Back to top

Actavis (ACT) Beats on Q4 Earnings & Revenues

Read MoreHide Full Article

Dublin, Ireland-based Actavis plc (ACT), is a specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The company, which was previously known as Watson Pharmaceuticals, Inc., became the third largest generics pharma company in the world following its Oct 2012 acquisition of Actavis Group.


Actavis has been actively pursuing deals to expand its portfolio especially its branded products offering. Having completed the acquisition of companies like Durata and Forest, Actavis is now set to acquire Botox maker, Allergan. With this acquisition, Actavis, which was previously known for its strong presence in the generics market, will find itself in the company of the top 10 pharmaceutical companies across the world based on sales.


Actavis’ earnings track record has been mostly good with the company delivering positive earnings surprises in the last four quarters with an average surprise of 3.35%. Estimate revisions are mostly positive with analysts upping their estimates for 2015.


Currently, ACT has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:


Huge Earnings Beat: ACT beat on fourth quarter earnings by a wide margin. Our consensus called for EPS of $3.65, and the company reported EPS of $3.91.


Revenue Beat: Actavis posted revenues of $4.01 billion, well above consensus estimates of $3.88 billion.


Key Stats: Actavis guided towards 2015 standalone earnings of $16.30 - $17.30 per share on revenues of about $15 billion. Actavis is slated to acquire Botox maker, Allergan, Inc. later this year.


Check back later for our full write up on this ACT earnings report later!


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

ADVSR-VICE ETF (ACT) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in